GBI Research, has released its
latest pharma report, "Acute Myeloid Leukemia Therapeutics Market to 2020
- Novel Therapies to Offer Clinical Benefit in Small Patient Cohorts"
Treatment and prognosis in AML is
strongly influenced by a patient's age, and their cytogenetic profile. In the
majority of cases these two prognostic influences are linked, with a higher
frequency of unfavorable cytogenetic abnormalities observed in the elderly.
Survival in this cohort of elderly patients is very poor, with a five year
overall survival of 3-8% (Luger, 2010). Despite a relatively advanced
understanding of genetic abnormalities associated with AML, the introduction of
targeted therapies is lagging in this indication in comparison to other cancers
such as breast and lung cancer, with no approved targeted therapies. Such slow
development may be a reflection of AMLs status as an orphan indication.
View
Full Report with TOC @ http://www.radiantinsights.com/research/acute-myeloid-leukemia-therapeutics-market-to-2020-novel-therapies-to-offer-clinical-benefit-in-small-patient-cohorts
Intensive treatment in eligible
patients (younger patients, and approximately 50% of diagnosed elderly
patients) is typically the combination of the two chemotherapeutic agents
cytarabine and daunorubicin, both of which were approved in the 1960s. In
patients ineligible for intensive first-line chemotherapy, options are very
poor, with the more recently approved Vidaza and Dacogen as the treatment options,
which both offer unsatisfactory survival. Across all newly diagnosed patients
that obtain complete remission, a stem cell transplant offers the highest
chance of long-term survival. However, this procedure is risky, with a higher
rate of treatment related mortality in the absence of better techniques to
reduce the risk of graft-versus-host disease.
The majority of patients
experience disease relapse, which is almost always fatal. Treatment options in
these patients typically involve the off-label use of chemotherapeutic agents,
whether in combination or as monotherapies.
About Radiant
Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
For More
Information, Visit Radiant
Insights
Contact:
Michelle
Thoras
Corporate
Sales Specialist, USA
Radiant
Insights, Inc
Phone:
1-415-349-0054
Toll
Free: 1-888-202-9519
Email:
sales@radiantinsights.com
Blog
URL: http://chemicalmaterialsmarket.blogspot.in/
No comments:
Post a Comment